Table 1 Previously published and current case of Immune checkpoint inhibitor-related acral vasculitis. Patient characteristics
Age/Gender | Cancer | ICI | Onset* | Skin lesions | Systemic symptoms | Immunological findings | CTCAE | Treatment/outcome of the IRAE | |
|---|---|---|---|---|---|---|---|---|---|
Comont et al. | 66/Male | Urothelial bladder cancer | Anti-CTLA4 (tremelimumab) Anti-PDL1 (durvalumab) | 8 | Periungual skin necrosis of several digits of both hands | None | ANAs (titer 5200, speckled pattern) | 3 | ICI discontinuation; Prednisone Complete resolution of IRAE |
Padda er al. | 52/Male | Melanoma | Anti-CTLA4 (ipilimumab) | 4 | Subungual necrosis on several upper and lower limb digits, rash | Myalgias, arthralgias, vision changes, jaw pain, interstitial pneumonia | None | 3 | ICI discontinuation; Methylprednisolone, prednisone, calcium channel blockers, nitropaste, poprostenol, botulinum toxin, sildenafil, rituximab Worsening of the IRAE requiring surgical amputation of multiple distal digits |
Leburel et al. | 60/Male | Melanoma | Anti-PDL1 (UKN) BRAF and MEK inhibitors (UKN) | 8 | Necrosis of 3 fingers and the heels | Arthralgia, dry mouth, paresthaesia of the feet and interstitial pneumonia | ANAs (titer 160, speckled pattern), Anti-SSA Abs Type III cryoglobulinemia | 3 | ICI discontinued; prednisone, calcium channel blockers, iloprost and acetylsalicylic acid Partial resolution of th.e IRAE |
Gambichler et al. | 60/Male | Melanoma | Anti-PD1 (nivolumab) Anti- CTLA4 (ipilimumab) | 3 | Subungual necrosis on the fingertips of both hands, severe gangrene | None | None | 4 | ICI discontinued after a second course of nivolumab; Prostacyclin, methylprednisolone Worsening of the IRAE requiring surgical amputation of multiple distal digits Progression of metastatic disease to multi-organ failure, leading to the death of the patient |